CLEO transitions into formal validation phase ahead of FDA submission
Cleo Diagnostics (ASX:COV) has completed the final development and preparation activities required to commence Analytical Validation (AV), the first formal regulatory study using its commercial assay. The milestone marks the ovarian cancer diagnostics company’s transition from research and optimisation work into formal data generation ahead of its planned FDA submission.
AV is expected to commence next month upon receipt of the first manufactured batch of CLEO’s test kits from Bio-Techne. On the current timeline, the Company anticipates an FDA 510(k) submission in H1 CY2027.
This represents a shift from development activity to formal regulatory data generation.
When big ASX news breaks, our subscribers know first
Inside the three-batch analytical validation program
Analytical Validation is the first formal regulatory study performed using CLEO’s commercial assay. Unlike the research, optimisation and development work completed to date, AV is conducted under a prescriptive FDA validation framework designed to demonstrate the analytical performance of the test kit against regulatory requirements.
Central to the study is a three-batch validation design. CLEO will evaluate three independently manufactured production batches to demonstrate assay reproducibility, manufacturing consistency and overall analytical robustness.
Key features of the AV program include:
-
AV is the first formal regulatory study performed using CLEO’s commercial assay.
-
The study is conducted under a prescriptive FDA validation framework, distinct from prior research and optimisation activities.
-
Three independently manufactured production batches will be assessed to demonstrate reproducibility, manufacturing consistency and analytical robustness.
-
Three additional Ella™ instruments have been commissioned and have now arrived at CLEO’s Melbourne facilities.
-
AV is expected to take ~4 months to complete, subject to any changes in the Bio-Techne manufacturing timeline.
Testing is due to commence upon receipt of CLEO’s first production batch of test kits, generating the first major analytical dataset supporting the planned FDA 510(k) submission.
Why analytical validation matters to investors
Successful completion of the three-batch validation program is expected to generate the analytical evidence required to progress to Clinical Validation (CV), the final study supporting CLEO’s planned FDA 510(k) submission. In practical terms, AV produces the data foundation on which the regulatory pathway advances, moving the Company closer to its disclosed submission target.
Understanding ovarian cancer diagnostics and the CXCL10 opportunity
Ovarian cancer has the highest five-year mortality rate of all cancers affecting women, with 51% of patients dying within five years. The primary drivers of this outcome are late diagnosis and the lack of effective screening tools, with many women diagnosed only after the disease has advanced.
CLEO’s patented technology is based on the CXCL10 biomarker, supported by over 15 years of scientific research and development. CXCL10 is produced early and at high levels in ovarian cancer but is largely absent in benign disease. This makes it a discriminator between malignant and non-malignant growths, which is central to the Company’s diagnostic approach.
The Company is executing a staged development strategy: starting with a pre-surgical triage test, then expanding into recurrence monitoring, and ultimately targeting global screening. CLEO describes this staged approach as creating clear value inflection points along the ovarian cancer detection pathway.
The remaining pathway to FDA submission
CLEO expects to progress through the following major regulatory milestones supporting its planned FDA submission:
-
Analytical validation (including testing of three production batches)
-
Finalisation of commercial assay algorithm
-
Clinical validation (including testing of pivotal clinical trial and control samples)
-
Clinical data analysis and trial results
-
FDA 510(k) submission
Preparations for Clinical Validation are already underway, including the engagement of an external laboratory and the finalisation of study protocols. Upon completion of AV, CV will evaluate the samples collected through the Company’s pivotal U.S. clinical trial, together with confounding condition samples and healthy individual samples, generating the clinical evidence package supporting the planned FDA submission.
The current milestone follows two recent steps in the pathway: the completion of patient recruitment and prospective blood sample collection for the pivotal U.S. clinical trial (ASX announcement dated 31 March 2026), and the commencement of kit manufacturing with Bio-Techne (ASX announcement dated 28 April 2026).
The pivotal U.S. clinical trial enrolled 624 women across 19 sites and secured 514 usable blood samples, surpassing the minimum recruitment threshold and generating the clinical sample set that will be evaluated during Clinical Validation following completion of the current AV program.
| Milestone | Description | Status / Timing |
|---|---|---|
| Analytical Validation | Three-batch test kit testing | Commencing next month, ~4 months |
| Algorithm Lock | Finalisation of commercial assay algorithm | Following AV |
| Clinical Validation | Trial, confounding and healthy samples | Preparations underway |
| Clinical Data Analysis | Trial results | Post-CV |
| FDA 510(k) Submission | Regulatory filing | H1 CY2027 |
Cleo Diagnostics announcement
“This major milestone follows the successful completion of patient recruitment and prospective blood sample collection for the Company’s pivotal U.S. clinical trial, and the commencement of CLEO’s kit manufacturing program with Bio-Techne.”
A staged development strategy addressing an unmet clinical need
The commencement of Analytical Validation marks the point at which CLEO shifts from development activity into formal regulatory data generation, a step that begins to build the evidence base required for FDA submission.
The Company has disclosed a clear timeline, targeting an FDA 510(k) submission in H1 CY2027, supported by a staged commercialisation strategy addressing a disease with high mortality and no effective screening tool.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.